Advertisement

Standard Chemotherapy Brings Longer Progression-Free Survival in Non-Small Cell Lung Cancer — Physician’s First Watch

Medical News |
April 9, 2014

Standard Chemotherapy Brings Longer Progression-Free Survival in Non-Small Cell Lung Cancer

By Kelly Young

Standard chemotherapy is associated with longer progression-free survival than the newer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in certain patients with advanced non-small cell lung cancer, according to a JAMA meta-analysis.

Researchers analyzed 11 randomized, open-label trials that compared a conventional chemotherapy agent with a first-generation EGFR TKI, such as erlotinib or gefitinib, in 1600 patients with wild-type EGFR tumors. Standard chemotherapy brought a longer median progression-free survival than EGFR TKI treatment (6.4 vs. 1.9 months). However, there was no difference between the groups in overall survival.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement